X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAB-185 is a fully human polyclonal antibody therapeutic, represents a highly-differentiated treatment option that provides a highly-specific match against the complexity, diversity, and the mutations SARS-CoV-2 presents.
Lead Product(s): SAB-185
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
SAB-185, a fully human polyclonal antibody therapeutic, represents a highly-differentiated treatment option that provides a highly-specific match against the complexity, diversity, and the mutations SARS-CoV-2 presents.
Lead Product(s): Human Polyclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $16.8 million Upfront Cash: Undisclosed
Deal Type: Termination January 18, 2023
Details:
SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
SAB has advanced its preclinical program, SAB-195, a polyclonal antibody treatment for C. diff., one of the most prevalent healthcare-associated bacterial infections in the US and the developed world.
Lead Product(s): SAB-195
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-195
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
SAB-195 is the First Fully-Human Polyclonal Antibody Treatment Providing Superior Efficacy For Treatment Of Clostridioides Difficile Infection (CDI) with dual mechanism of action designed to treat severe CDI and reduce CDI recurrence in high-risk patients.
Lead Product(s): SAB-195
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-195
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brookline Capital Markets
Deal Size: $7.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 07, 2022
Details:
SAB-142 is fully-human therapeutic that may be administered multiple times without inducing immune-mediated reactions including immediate anaphylaxis or delayed serum sickness.
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
The agreement also provides the opportunity for Emergent to utilize SAB’s novel DiversitAb™ platform, the only one in the world that produces fully-human polyclonal antibodies utilizing transchromosomic cows, for future development of SAB-176 and other programs.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Emergent BioSolutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
